ZyVersa Therapeutics Valuation
| ZVSA Stock | 1.26 0.04 3.08% |
Today, the company appears to be undervalued. ZyVersa Therapeutics maintains a prevalent Real Value of USD1.56 per share. The last-minute price of the company is USD1.26. Our model calculates the value of ZyVersa Therapeutics from examining the company fundamentals such as Shares Owned By Insiders of 0.61 %, current valuation of (1.73 M), and Return On Asset of -0.25 as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting ZyVersa Therapeutics' valuation include:
Price Book 0.162 | Enterprise Value -1.7 M | Enterprise Value Ebitda (2.21) | Trailing PE 0.0011 |
Undervalued
Today
Please note that ZyVersa Therapeutics' price fluctuation is abnormally volatile at this time. Calculation of the real value of ZyVersa Therapeutics is based on 3 months time horizon. Increasing ZyVersa Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since ZyVersa Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of ZyVersa Stock. However, ZyVersa Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.26 | Real 1.56 | Target 2.5 | Hype 1.28 | Naive 1.03 |
The real value of ZyVersa Stock, also known as its intrinsic value, is the underlying worth of ZyVersa Therapeutics Company, which is reflected in its stock price. It is based on ZyVersa Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of ZyVersa Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of ZyVersa Therapeutics helps investors to forecast how ZyVersa stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of ZyVersa Therapeutics more accurately as focusing exclusively on ZyVersa Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use ZyVersa Therapeutics' intrinsic value based on its ongoing forecasts of ZyVersa Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against ZyVersa Therapeutics' closest peers. If more than one evaluation category is relevant for ZyVersa Therapeutics we suggest using both methods to arrive at a better estimate.
ZyVersa Therapeutics Cash |
|
ZyVersa Valuation Trend
Comparing ZyVersa Therapeutics' enterprise value against its market capitalization is a good way to estimate the value of ZyVersa Therapeutics uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
ZyVersa Therapeutics Total Value Analysis
ZyVersa Therapeutics is at this time projected to have valuation of (1.73 M) with market capitalization of 1.4 M, debt of 8.66 K, and cash on hands of . The negative valuation of ZyVersa Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the ZyVersa Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(1.73 M) | 1.4 M | 8.66 K |
ZyVersa Therapeutics Asset Utilization
One of the ways to look at asset utilization of ZyVersa is to check how much profit was generated for every dollar of assets it reports. ZyVersa Therapeutics maintains a negative usage of resources of -0.25 (%), losing USD0.002492 for each dollar of resources held by the company. Inadequate asset utilization attests that the company is being less effective with each dollar of resources it maintains. Specifically, asset utilization of ZyVersa Therapeutics shows how discouraging it operates for each dollar spent on its resources.ZyVersa Therapeutics Ownership Allocation
Roughly 94.22 (%) of ZyVersa Therapeutics outstanding shares are held by general public with 0.61 % owned by insiders and only 5.17 percent by institutional investors.ZyVersa Therapeutics Profitability Analysis
Net Loss for the year was (98.3 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates ZyVersa Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in ZyVersa Therapeutics and how it compares across the competition.
About ZyVersa Therapeutics Valuation
The stock valuation mechanism determines ZyVersa Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of ZyVersa Therapeutics. We calculate exposure to ZyVersa Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of ZyVersa Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -9.4 K | -9.8 K |
ZyVersa Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 97.5 K |
ZyVersa Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of ZyVersa Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value ZyVersa we look at many different elements of the entity such as ZyVersa's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as ZyVersa Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use ZyVersa Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes ZyVersa Therapeutics' worth.Complementary Tools for ZyVersa Stock analysis
When running ZyVersa Therapeutics' price analysis, check to measure ZyVersa Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ZyVersa Therapeutics is operating at the current time. Most of ZyVersa Therapeutics' value examination focuses on studying past and present price action to predict the probability of ZyVersa Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ZyVersa Therapeutics' price. Additionally, you may evaluate how the addition of ZyVersa Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |